Halozyme Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
August 9, 2016 4:12 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior... More
